Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (1): 16-21.doi: 10.35541/cjd.20220390
• Guidelines and Consensus • Previous Articles Next Articles
Rosacea Research Center, Chinese Society of Dermatology; Rosacea Professional Committee, China Dermatologist Association
Received:2022-06-01
Revised:2022-11-07
Online:2023-01-15
Published:2023-01-03
Contact:
Li Ji; Song Weimin
E-mail:liji_xy@csu.edu.cn; doctorsong@126.com
Rosacea Research Center, Chinese Society of Dermatology, Rosacea Professional Committee, China Dermatologist Association. Expert consensus on intradermal injections with botulinum toxin A for the treatment of flushing and persistent erythema caused by rosacea[J]. Chinese Journal of Dermatology, 2023, 56(1): 16-21.doi:10.35541/cjd.20220390
| ［1］ | Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA［J］. J Drugs Dermatol, 2012,11（12）:e76⁃e79. |
| ［2］ | 张二佳, 林彤. A型肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 中国麻风皮肤病杂志, 2021,37（9）:610⁃613. doi: 10.12144/zgmfskin202109610. |
| ［3］ | 曾黛琳, 于波, 吴琳. 肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 实用皮肤病学杂志, 2021,14（5）:297⁃300. doi: 10.11786/sypfbxzz.1674⁃1293.20210510. |
| ［4］ | Bloom BS, Payongayong L, Mourin A, et al. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea［J］. Dermatol Surg, 2015,41 Suppl 1:S9⁃16. doi: 10.1097/DSS. 0000000000000277. |
| ［5］ | Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double⁃blind, placebo⁃controlled, split⁃face pilot study in rosacea patients with facial erythema［J］. Dermatol Surg, 2019,45（9）:1155⁃1162. doi: 10. 1097/DSS.0000000000001819. |
| ［6］ | Sundaram H, Signorini M, Liew S, et al. Global aesthetics consensus: botulinum toxin type a⁃⁃evidence⁃based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications［J］. Plast Reconstr Surg, 2016,137（3）:518e⁃529e. doi: 10.1097/01.prs. 0000475758.63709.23. |
| ［7］ | 中华医学会整形外科学分会微创美容专业学组. A型肉毒毒素用于面部医学美容的临床专家共识［J］. 中华整形外科杂志, 2018,34（10）:791⁃795,802. doi: 10.3760/cma.j.issn.1009⁃4598.2018.10.001. |
| ［8］ | 中国医师协会皮肤科医师分会注射美容亚专业委员会. 肉毒毒素注射在皮肤美容中应用的专家共识［J］. 中国美容医学, 2017,26（8）:3⁃8. |
| ［9］ | 肉毒毒素治疗应用专家组, 中华医学会神经病学分会帕金森病及运动障碍学组. 中国肉毒毒素治疗应用专家共识［J］. 中华神经科杂志, 2018,51（10）:779⁃786. doi: 10.3760/cma.j.issn.1006⁃7876.2018.10.002. |
| ［10］ | Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2018,78（1）:148⁃155. doi: 10.1016/j.jaad.2017.08.037. |
| ［11］ | Thiboutot D, Anderson R, Cook⁃Bolden F, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2020,82（6）:1501⁃1510. doi: 10.1016/j.jaad.2020.01. 077. |
| ［12］ | 中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）［J］. 中华皮肤科杂志, 2021,54（4）:279⁃288. doi: 10.35541/cjd.20201078. |
| ［13］ | 汪犇, 赵志祥, 简丹, 等. 中国玫瑰痤疮临床特征分析和诊断标准再探讨［J］. 中华皮肤科杂志, 2020,53（9）:675⁃679. doi: 10.35541/cjd.20200376. |
| ［14］ | Schaller M, Dirschka T, Lonne⁃Rahm SB, et al. The importance of assessing burning and stinging when managing rosacea: a review［J］. Acta Derm Venereol, 2021,101（10）:adv00584. doi: 10.2340/actadv.v101.356. |
| ［15］ | Tan J, Steinhoff M, Bewley A, et al. Characterizing high⁃burden rosacea subjects: a multivariate risk factor analysis from a global survey［J］. J Dermatolog Treat, 2020,31（2）:168⁃174. doi: 10. 1080/09546634.2019.1623368. |
| ［16］ | Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea［J］. J Investig Dermatol Symp Proc, 2011,15（1）:53⁃62. doi: 10.1038/jidsymp.2011.6. |
| ［17］ | Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea⁃affected skin［J］. Arch Dermatol Res, 2012,304（2）:133⁃137. doi: 10.1007/s00403⁃011⁃1177⁃1. |
| ［18］ | Báez A, Paleari J, Durán MN, et al. Frey syndrome secondary to submaxillectomy and botulinic treatment［J］. Medicina （B Aires）, 2007,67（5）:478⁃480. |
| ［19］ | Khan TT, Herne K, Dayan SH, et al. Facial blanching due to neurotoxins: proposed mechanisms［J］. Dermatol Surg, 2013,39（1 Pt 1）:24⁃29. doi: 10.1111/dsu.12057. |
| ［20］ | Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea［J］. F1000Res, 2018,7:1885. doi: 10. 12688/f1000research.16537.1. |
| ［21］ | Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action［J］. Arq Neuropsiquiatr, 2005,63（1）:180⁃185. doi: 10.1590/s0004⁃282x2005000100035. |
| ［22］ | Choi JE, Di Nardo A. Skin neurogenic inflammation［J］. Semin Immunopathol, 2018,40（3）:249⁃259. doi: 10.1007/s00281⁃018⁃0675⁃z. |
| ［23］ | Kellogg DL Jr, Zhao JL, Wu Y, et al. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans［J］. J Appl Physiol （1985）, 2012,113（10）:1512⁃1518. doi: 10.1152/japplphysiol.00859.2012. |
| ［24］ | Mascarenhas NL, Wang Z, Chang YL, et al. TRPV4 mediates mast cell activation in cathelicidin⁃induced rosacea inflammation［J］. J Invest Dermatol, 2017,137（4）:972⁃975. doi: 10.1016/j.jid.2016.10.046. |
| ［25］ | Wang L, Wang YJ, Hao D, et al. The theranostics role of mast cells in the pathophysiology of rosacea［J］. Front Med （Lausanne）, 2019,6:324. doi: 10.3389/fmed.2019.00324. |
| ［26］ | Choi JE, Werbel T, Wang Z, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation［J］. J Dermatol Sci, 2019,93（1）:58⁃64. doi: 10.1016/j.jdermsci.2018.12.004. |
| ［27］ | Pickett A. Can botulinum toxin cause anaphylaxis after an aesthetic treatment?［J］. Clin Exp Dermatol, 2018,43（5）:599⁃600. doi: 10.1111/ced.13342. |
| ［28］ | Gheisari M, Moslemi Haghighi S, Baghani M, et al. Generalized drug eruption with vasculopathic reaction pattern to botulinum toxin injection［J］. Dermatol Ther, 2020,33（6）:e14294. doi: 10.1111/dth.14294. |
| ［29］ | Grassegger A. Comment on Tamura et al′s Allergic reaction to botulinum toxin: positive intradermal test［J］. Dermatol Surg, 2009,35（6）:1015. doi: 10.1111/j.1524⁃4725.2009.01176.x. |
| ［30］ | Cohen JL, Scuderi N. Safety and Patient Satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review［J］. Aesthet Surg J, 2017,37（suppl_1）:S32⁃S44. doi: 10.1093/asj/sjx010. |
| ［31］ | Wu W. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects［J］. Plast Reconstr Surg, 2015,136（5 Suppl）:92S⁃100S. doi: 10.1097/PRS.000000 0000001827. |
| ［32］ | Chen Y, Hua W, Li A, et al. Analysis of facial redness by comparing VISIA（®） from Canfield and CSKIN（®） from Yanyun Technology［J］. Skin Res Technol, 2020,26（5）:696⁃701. doi: 10.1111/srt.12856. |
| ［33］ | Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long⁃lasting results［J］. Br J Dermatol, 2008,159（3）:628⁃632. doi: 10.1111/j.1365⁃2133.2008.08702.x. |
| ［34］ | Carruthers J, Carruthers A. The effect of full⁃face broadband light treatments alone and in combination with bilateral crow′s feet Botulinum toxin type A chemodenervation［J］. Dermatol Surg, 2004,30（3）:355⁃366. doi: 10.1111/j.1524⁃4725.2004. 30101.x. |
| ［35］ | Khoury JG, Saluja R, Goldman MP. The effect of botulinum toxin type A on full⁃face intense pulsed light treatment: a randomized, double⁃blind, split⁃face study［J］. Dermatol Surg, 2008,34（8）:1062⁃1069. doi: 10.1111/j.1524⁃4725.2008.34207.x. |
| ［36］ | Al⁃Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type⁃A in the treatment of rosacea⁃associated erythema and flushing［J］. Dermatol Ther, 2020,33（6）:e13976. doi: 10.1111/dth.13976. |
| ［37］ | Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1775⁃1791. doi: 10.1111/jdv.14349. |
| [1] | Xu Zhongyi, Xing Xiaoxue, Dong Yaqi, Zhang Chengfeng, Xiang Leihong. Retrospective analysis of clinical manifestations and treatment outcomes in 254 patients with melasma in a tertiary grade-A hospital in Shanghai [J]. Chinese Journal of Dermatology, 2025, 58(9): 808-815. |
| [2] | Wang Chen, Ding Yuecen, Dong Yaqi, Zhang Chengfeng, Xiang Leihong, Xu Zhongyi. Diagnosis and treatment of acquired dermal macular hyperpigmentation [J]. Chinese Journal of Dermatology, 2025, 58(9): 873-877. |
| [3] | Zhu Tingting, Li Weiran, Pan Zhaobing, Liu Hao, Tang Xianfa, Zhu Caihong, Huang Hequn, Duan Dawei, Zhang Ruochen, Chen Xiaojian, Wang Yang, Xue Qian, Zhang Jurui, Yang Lijing, Zhang Xuejun, Huang He, Zhang Bo, . Efficacy of baricitinib combined with ruxolitinib cream in the treatment of six patients with progressive nonsegmental vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2025, 58(9): 856-859. |
| [4] | Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of an antioxidant gel containing tea polyphenols combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(9): 834-838. |
| [5] | Luo Shuaihantian, Long Hai, Lu Qianjin. Research advances in systemic lupus erythematosus in 2024 [J]. Chinese Journal of Dermatology, 2025, 58(8): 777-780. |
| [6] | Acne Study Group of China Dermatologist Association, Dermatology Professional Committee of Chinese Research Hospital Association, Acne Study Group of Dermatology and Venereology Professional Committee of Chinese Association of Integrative Medicine. Chinese expert consensus on clinical severity grading and therapeutic evaluation of acne vulgaris （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(8): 709-714. |
| [7] | Xue Ke, Chen Jia, Li Bin. Targeted therapy for systemic lupus erythematosus [J]. Chinese Journal of Dermatology, 2025, 58(8): 781-784. |
| [8] | Lu Qianjin, Cao Shumei, Jiang Jiao. Lupus erythematosus research: current status and challenges [J]. Chinese Journal of Dermatology, 2025, 58(8): 715-728. |
| [9] | Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the diagnosis and treatment of localized scleroderma （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(8): 699-708. |
| [10] | Lyu Shuying, Wang Ying, Lin Wenjun, Yang Dingquan. Efficacy of combination therapy with tofacitinib in the treatment of alopecia ophiasis: a retrospective analysis of 21 cases [J]. Chinese Journal of Dermatology, 2025, 58(7): 630-635. |
| [11] | Hair Research Group, Chinese Society of Dermatology. Chinese expert consensus on the diagnosis and treatment of lichen planopilaris/frontal fibrosing alopecia （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(7): 583-590. |
| [12] | Wei Ran, Li Qinfeng. Novel targeted drugs for the treatment of pediatric alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 650-653. |
| [13] | Chinese Society of Dermatology, China Dermatologist Association. Recommendations for the diagnosis and treatment pathway for hereditary angioedema:a dermatology expert group consensus （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(6): 497-502. |
| [14] | Huang Hejin, Li Xinya, He Ziqing, Xi Wenwen, Tang Yujun, Zhang Jianfei, Xiao Xia, Jiang Bin, Yang Feng. Postoperative complications in 3 000 patients with axillary osmidrosis after minimally invasive rotary cutting surgery: a retrospective study [J]. Chinese Journal of Dermatology, 2025, 0(5): 20230291-e0230291. |
| [15] | The Consensus Development Expert Group on Diagnosis and Treatment of Port-wine Stain in Chinese Children, Pediatric Dermatologist Committee, China Dermatologist Association. Expert consensus on diagnosis and treatment of port-wine stain in children （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 396-404. |
|
